Norges Bank
GENB

Norges Bank’s Generate Biomedicines GENB Stock Holding History

Norges Bank’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.3M Buy
+2,094,616
New +$28.5M ﹤0.01% 1108

Other funds holding GENB

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCP
Davern Capital Partners Ny, New York $587M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank's GENB Position: Q2 2026 in Review

Norges Bank opened a new position in Generate Biomedicines (GENB) in Q2 2026: 2,094,616 shares worth $35.3M. The stake represents ﹤0.01% of the portfolio and ranks #1108 among its holdings.

51 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Norges Bank held 2,094,616 shares of Generate Biomedicines worth $35.3M as of Q2 2026.
  • Generate Biomedicines was a new Norges Bank position in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of Norges Bank's portfolio in Q2 2026, its #1108 holding.
  • 51 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.